Journal
FUTURE ONCOLOGY
Volume 16, Issue 12, Pages 705-715Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2020-0163
Keywords
antibody-drug conjugate; HER2-negative; HR-positive; MBC; metastatic breast cancer; sacituzumab govitecan; SN-38; Trop-2
Categories
Funding
- Immunomedics, Inc.
- Pfizer
- Novartis
- Eli Lilly
- F. Hoffmann-La Roche
- Macrogenics
- Merck
- OBI Pharma
- Eisai
- Daiichi Sankyo
- Odonate
- Seattle Genetics
- Genentech/F Hoffman-La Roche
- Sanofi
- Radius Health
- Immunomedics
- Mersana Therapeutics
- Innocrin Pharmaceuticals
- Biothernostics
- AstraZeneca
- Nektar Therapeutics
- Genentech/F. Hoffmann-La Roche
- NanoString Technologies
- Exelixis
- Cyclacel
- Bristol-Myers Squibb
- Bayer HealthCare Pharmaceuticals
- Takeda
- F Hoffmann-La Roche
- ARIAD Pharmaceuticals
- Baxalta GMBH/Servier Affaires
- Guardant Health
- Merck Sharp Dohme
- PIQUR Therapeutics
- Puma Biotechnology
- Queen Mary University of London
- GlaxoSmithKline
- Contessa
- Merck, Sharp Dohme
- Genentech/F Hoffmann-La Roche
- OncoGenex Pharmaceuticals
Ask authors/readers for more resources
Patients with HR+/HER2- metastatic breast cancer (MBC) whose cancers have progressed despite conventional therapies represent an unmet clinical need. Trop-2, a transmembrane calcium signal transducer, is highly expressed in MBC and plays a role in tumor growth and progression. Sacituzumab govitecan (SG) is a novel antibody-drug conjugate comprising an Trop-2 antibody coupled to SN-38, the active metabolite of irinotecan, via a unique hydrolyzable linker. SG has demonstrated promising activity in a Phase I/II IMMU-132-01 basket study in heavily pretreated solid tumors, including HR+/HER2- MBC. We describe the registrational Phase III TROPiCS-02 study (NCT03901339), evaluating SG versus treatment of physician's choice in HR+/HER2- MBC. Trial registration number: NCT03901339.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
